Australia is carefully awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://saadjqhq615052.wikitidings.com/7497216/novo_nordisk_s_retatrutide_australia_a_potential_breakthrough_for_weight_management